Dr. Karin Rosén, Board member of Diamyd Medical – Moderated by Julie Ames from Ventures Accelerated
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Dr. Karin Rosén, Board member of Diamyd Medical – Moderated by Julie Ames from Ventures Accelerated
-
Narrated by:
-
By:
How does Nordic life science innovation translate into global impact? In this episode of the SACC New England Podcast, we explore how new discoveries about the immune system are shaping the future of diabetes research.
Moderator Julie Ames speaks with Dr. Karin Rosén, physician-scientist and board member of Diamyd Medical, a Swedish biotech company developing a therapy designed to help preserve the body’s own insulin production. Together, they discuss the science behind immune tolerance, the company’s ongoing Phase 3 clinical trial, and why the U.S. market plays a critical role in scaling Nordic biotech innovation.
Hosted on Acast. See acast.com/privacy for more information.
adbl_web_anon_alc_button_suppression_t1
No reviews yet